The most played episodes among Podcast App listeners.

1. 1
   Number 1: AKT Inhibition in Prostate Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

   Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics: Tolerability of capivasertib and management of associated side effects — Question from Neeraj Agarwal, MD, FASCO (0:00) Case: A man in his early 70s with Type 2 diabetes presents with metastatic hormone-sensitive prostate cancer with widespread bone metastases and PTEN deficiency on next-generation sequencing and receives relugolix/darolutamide — Rana R McKay, MD, FASCO (8:39) CME information and select publications

   September 05, 2026·18min
   Play
2. 2
   Number 2: ER-Positive, HER2-Positive Metastatic Breast Cancer — Patterns of Care Among Community Oncologists

   Featuring perspectives from Dr Lisa A Carey and Dr Maha Hussain, including the following topics: Introduction (0:00) HER2 History (1:32) Cases from the GMO Survey (7:06) Biology and Selection of First-Line Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer (mBC) — Dr Mahtani (19:56) Faculty Case Presentations (31:37) Patterns of Care Survey — Part 1 (38:26) Optimizing the Use of Up-Front Maintenance Therapy for HER2-Positive mBC — Dr Carey (44:53) Faculty Case Presentations (54:13) CME information and select publications

   September 03, 2026·59min
   Play
3. 3
   Number 3: Metastatic Triple-Negative Breast Cancer — Patterns of Care

   Featuring perspectives from Prof Peter Schmid and Dr Melinda Telli, including the following topics: Introduction: TROP2-Targeting Antibody-Drug Conjugates (ADCs) for Metastatic Triple-Negative Breast Cancer (0:00) First-Line Therapy (PD-L1 Negative) (6:53) First-Line Therapy (PD-L1 Positive) (23:40) Second-Line Therapy (Sequencing) (34:08) Adverse Events with TROP2-Targeting ADCs (43:43) CME information and select publications

   August 28, 2026·1h 3min
   Play
4. 4
   Number 4: Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer | Hope S Rugo, MD

   Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances Involving the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer | Faculty Presentation 2: Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Hope S Rugo, MD CME information and select publications

   August 23, 2026·45min
   Play
5. 5
   Number 5: Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer | Virginia Kaklamani, MD, DSc

   Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances Involving the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer | Faculty Presentation 1: Identification of Appropriate Candidates with HR-Positive Metastatic Breast Cancer (mBC) for Agents Targeting the PI3K/AKT/mTOR Pathway; Role in the Up-Front Setting — Virginia Kaklamani, MD, DSc CME information and select publications

   August 23, 2026·15min
   Play